Clinical Research Directory

Inclusion Criteria: * Histologically conformed initial metastatic non-keratinizing nasopharyngeal carcinoma (according to the 8th edition of AJCC/UICC stage system) and no PD was observed in eligible patients after comprehensive treatment (chemotherapy±immunotherapy+radiotherapy to primary tumor). Then, the metastic lesions were PR/SD, and met the following requirement: the metastatic lesions ≤5 and metastatic organs ≤2, no more than 3 metastastic lesions for a single organ (diameter ≤ 5cm) * age 18-70 years old * Karnofsky scores ≥70 * Estimated life ≥ 6 months * Adequate organ function including the following: Absolute neutrophil count (ANC) \>= 2.0 \* 109/l; Platelets count \>= 100 \* 109/l ;Hemoglobin \>= 90 g/dl; Creatinine clearance \>= 60 ml/min; For patients without liver metastasis, AST and ALT \<= 1.5 times institutional upper limit of normal (ULN), Total bilirubin \<= 1.5 times institutional ULN; For patients with liver metastasis, AST and ALT \<= 3 times institutional upper limit of normal (ULN), Total bilirubin \<= 3 times institutional ULN, with normal coagulation function, child-pugh grade A or B, normal liver tissue volume \>700 mL * Signed written informed consent Exclusion Criteria: * Patients who achieve complete remission after comprehensive treatment * Pathology confirmed as second primary tumor * Received radiotherapy at the corresponding site before, and overlapped with the site of this radiotherapy * Femoral bone metastasis * With serious medical complications and contraindications of radiotherapy * With uncontrollable malignant pleural effusion * Positive pregnancy test for women of childbearing age or lactating women * Uncontrolled or active infections, such as immunodeficiency or HIV infection * Active mental disorder or other mental disorder that affects the patient's ability to sign informed consent and understanding.